上海科弈药业科技

Keyi Bio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to the discovery and development of innovative cancer immunotherapies. The company leverages three core technology platforms: next-generation CAR-T cell therapies, bispecific antibodies, and small molecule targeted drugs. Its pipeline includes several promising candidates, such as KY-0118, a Claudin 18.2-targeted CAR-T therapy for gastric cancer, and KY-0120, a BCMA-targeted therapy for multiple myeloma. Keyi Bio aims to overcome the limitations of current treatments by focusing on dual-targeting strategies and improving the persistence of cell therapies in solid tumors. The company maintains integrated research, development, and GMP manufacturing capabilities to accelerate its clinical programs. With a strong focus on oncology, Keyi Bio is positioned to address significant unmet needs in both hematological and solid malignancies.